Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of single IV doses of Onicit® (Palonosetron) 0.25 mg in the prevention of acute and delayed nausea and vomiting associated with moderate and highly emetogenic chemotherapy.
Neoplasms|Nausea|Vomiting
DRUG: Palonosetron
Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication., During 24 hours after administration of chemotherapy.
Proportion of patients who achieved a CR and of those who achieved complete control, Days 1 to 5 at different time intervals for each secondary outcome.|Number of emetic episodes, Days 1 to 5 at different time intervals for each secondary outcome.|Time to first emetic episode; time to administration and need for rescue therapy; and to treatment failure time to first emetic episode or administration of rescue medication, Days 1 to 5 at different time intervals for each secondary outcome.
The purpose of this study is to evaluate the efficacy and safety of single IV doses of Onicit® (Palonosetron) 0.25 mg in the prevention of acute and delayed nausea and vomiting associated with moderate and highly emetogenic chemotherapy.